Search Results

The inhibition of the host's natural immune response by tumor cells was widely reported in the early phases of the development of oncology therapy, and the concept of employing the host's immune system to treat cancer, i.e. tumor immunotherapy, is not new. However, as a result of early theoretical constraints, clinical application of immunotherapy did not go smoothly and lagged significantly behind radiation and chemotherapy. The path has been winding, but the future now seems promising. Immunotherapy research has advanced enormously as a result of the maturing of immuno-editing theory and the creation of numerous technologies, despite a number of unsuccessful endeavors and clinical studies. Since around 1998, the US Food and Drug Administration (FDA) has approved a variety of tumor immunotherapies, including cytokines (interleukin-2, interferons), cancer vaccines (Provenge), immune checkpoint inhibitors (ipilimumab), and cellular therapies (chimeric antigen receptor-T (CAR-T)), signaling a boom in the field.
Cancer Vaccines/therapeutic use* ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Interferons ; Interleukin-2/therapeutic use* ; Ipilimumab ; Neoplasms/pathology* ; Receptors, Chimeric Antigen

1.Application of interferon in the treatment of liver cancer.

2.Responsive factors and predictors of interferon treatment in patients with chronic hepatitis B.

3.Role of pegylated-interferon in the treatment of hepatitis C in Chinese patients.

4.The role of interferon in the treatment of viral hepatitis and its perspective.

5.Interferons for treating chronic hepatitis B.

6.Interferons and chronic hepatitis C treatment.

7.Latest advances in anti-virus therapy for hepatitis B: A report from the 55th Annual Meeting of the American Association for the Study of Liver Diseases.

8.Focusing on the treatment of chronic hepatitis B.

9.Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia.

10.Cancer immunotherapy: an evolving paradigm.

Display Mode

Output Records

File Type